Radiopharm Theranostics Limited

Radiopharm Theranostics Limited is a clinical-stage biopharmaceutical company dedicated to developing innovative radiopharmaceutical products for the diagnosis and treatment of cancer. Headquartered in Carlton, Victoria, Australia, the company's mission is to redefine oncology care by delivering first-in-class radiopharmaceuticals, enabling individuals with cancer to live longer and fuller lives.

The company's pipeline focuses on distinct radiopharmaceutical technologies, including nanobodies, antibodies, small molecules, and peptides, designed to address significant unmet needs in oncology. Radiopharm Theranostics is advancing both diagnostic and therapeutic applications across various solid tumor cancers, such as lung, breast, prostate, and brain metastases. Key programs include RAD101 for brain metastases imaging, RAD202 for HER2-targeted therapy, RAD402 for advanced prostate cancer, and RV-01 targeting B7H3.

Led by Managing Director and CEO Riccardo Canevari and Founder and Executive Chairman Paul Hopper, Radiopharm Theranostics has achieved several notable milestones. In April 2026, the company completed enrollment in its Phase 2b clinical trial for RAD 101 in brain metastases imaging and presented initial findings from its Phase 1 HEAT clinical trial for 177Lu-RAD202 at the American Association for Cancer Research 2026. Radiopharm also secured an IND approval from the US FDA for a Phase 1 therapeutic clinical study for RV-01 and signed a supply agreement with Siemens Healthineers for RAD101. The company further strengthened its strategic position by increasing its ownership in Radiopharm Ventures, a joint venture with MD Anderson Cancer Center, to 87.5% in January 2026.